Is It Time to Buy Biotechnology Stocks?

  • 📰 Investingcom
  • ⏱ Reading Time:
  • 30 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 53%

Nederland Nieuws Nieuws

Nederland Laatste Nieuws,Nederland Headlines

Stocks Analysis by Michele Schneider covering: Vertex Pharmaceuticals Inc, Gilead Sciences Inc, iShares Biotechnology ETF, Amgen Inc. Read Michele Schneider's latest article on Investing.com

Furthermore, and even more interesting, is that the ETF does not really reflect the big movers. Rather, IBB is holding as a result but not flying.On the Daily chart, what is not shown here is the July 6-month calendar range low at 124.11.Hence, we feel good calling 124 the bottom of the trading range and risk point.Again, IBB traded above that in early 2023, when it soared to 138.

However, since then, 130-132 has been resistance. We feel good calling that level the top of the trading range. As far as other indicators, Real Motion looks like a double bottom from early July and now, although we would like to see more momentum.Our Leadership indicator shows IBB outperforming SPDR® S&P 500 on a daily timeframe but still underperforming on a weekly basis.437 is the July 6-month calendar range low-will look for a return above or a trip to 420Relative strength here-a return over 346 PositiveOutperformer as all this did was fall to the July range high at 44.

Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder:

 /  🏆 450. in NL
 

Bedankt voor uw reactie. Uw reactie wordt na beoordeling gepubliceerd.

Nederland Laatste Nieuws, Nederland Headlines

Similar News:Je kunt ook nieuwsberichten lezen die vergelijkbaar zijn met deze die we uit andere nieuwsbronnen hebben verzameld.

Hong Kong stocks fall for seventh day as Japanese stocks gainAsia-Pacific stocks mostly increased Monday, Aug. 21, with shares in Hong Kong declining for the seventh day. Hong Kong stocks dropped, with the Hang Seng...
Bron: MarketWatch - 🏆 3. / 97 Lees verder »